Drug that could slow womb cancer to be rolled out by NHS in England

Dostarlimab or Jemperli, an immunotherapy used alongside chemotherapy, could extend life expectancy

A drug that could improve the quality of life of hundreds of women with womb cancer will be rolled out on the NHS across England from Tuesday.

Dostarlimab, also known as Jemperli, is an immunotherapy that works by attracting specific proteins on the surface of cancer cells to help the immune system attack them.